Statins and Cardiac Allograft Vasculopathy after Heart Transplantation

ABSTRACT

Coronary artery disease in the transplanted heart, also known as cardiac allograft vasculopathy, is one of the major causes of mortality late after heart transplantation. There are multiple immune and nonimmune risk factors associated with this disease process, one of which is hyperlipidemia. Use of lipid-lowering agents, specifically 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) was initially reported to have outcomes benefit and possibly immunosuppressive effects in a single-center study of heart transplant recipients. Other subsequent studies have supported this beneficial effect. Hyperlipidemia is associated with immune activity, particularly with respect to oxidation-sensitive signaling pathways. By lowering lipids, statins can ameliorate this immune activity, but it has been a matter of contention as to whether statins have cholesterol-independent immune-modulating effects. In two recent papers, cholesterol-independent immune effects of statins have been reported, including repressed induction of major histocompatibility complex class II by interferon-gamma, and selective blocking of leukocyte function antigen 1, both of which reduce the activation of T lymphocytes. The clinical reports demonstrating outcomes benefits in heart transplant recipients and recent laboratory publications that report an immunomodulatory effect of statins provide a firm scientific rationale to support the routine use of statins in heart transplant patients.

KEYWORDS

Heart transplantation - cardiac allograft vasculopathy - statins - outcomes

REFERENCES

• 1 Johnson M R. Transplant coronary disease: non-immunologic risk factors.  J Heart Lung Transplant. 1992;  11 S124-S132
• 2 Valantine H. Role of lipids in allograft vascular disease: a multicenter study of intimal thickening detected by intravascular ultrasound.  J Heart Lung Transplant. 1995;  14 S234-S237
• 3 Stamler J S, Vaughan D E, Rudd M A et al.. Frequency of hypercholesterolemia after cardiac transplantation.  Am J Cardiol. 1988;  62 1268-1272
• 4 Superko H R, Haskell W L, Di Ricco C D. Lipoprotein and hepatic lipase activity and high-density lipoprotein subclasses after cardiac transplantation.  Am J Cardiol. 1990;  66 1131-1134
• 5 Kobashigawa J A, Kasiske B L. Hyperlipidemia in solid organ transplantation.  Transplantation. 1997;  63 331-338
• 6 Eich D, Thompson J A, Ko D J et al.. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease.  J Heart Lung Transplant. 1991;  10 45-49
• 7 Esper E, Glagov S, Karp R B et al.. Role of hypercholesterolemia in accelerated transplant coronary vasculopathy: results of surgical therapy with partial ileal bypass in rabbits undergoing heterotopic heart transplantation.  J Heart Lung Transplant. 1997;  16 420-435
• 8 Kapadia S R, Nissen S E, Ziada K M et al.. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study.  J Am Coll Cardiol. 2001;  38 206-213
• 9 Alonso D R, Starek P K, Minick C R. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia.  Am J Pathol. 1977;  87 415-442
• 10 Tanaka H, Sukhova G K, Libby P. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts.  Arterioscler Thromb. 1994;  14 734-745
• 11 Raisanen-Sokolowski A, Tilly-Kiesi M, Ustinov J et al.. Hyperlipidemia accelerates allograft arteriosclerosis (chronic rejection) in the rat.  Arterioscler Thromb. 1994;  14 2032-2042
• 12 Shepherd J, Cobbe S M, Ford I et al.. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.  N Engl J Med. 1995;  333 1301-1307
• 13 Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-1389
• 14 Sacks F M, Pfeffer M A, Moye L A et al.. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.  N Engl J Med. 1996;  335 1001-1009
• 15 Ridker P M, Rifai N, Pfeffer M A et al.. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.  Circulation. 1998;  98 839-844
• 16 Kobashigawa J A, Katznelson S, Laks H et al.. Effect of pravastatin on outcomes after cardiac transplantation.  N Engl J Med. 1995;  333 621-627
• 17 Cutts J L, Scallen T J, Watson J, Bankhurst A D. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity.  J Cell Physiol. 1989;  139 550-557
• 18 Kobashigawa J, Moriguchi J, Cogert G et al.. 10-year results of the pravastatin randomized trial in heart transplant recipients.  J Heart Lung Transplant. 2004;  23 S115
• 19 Wenke K, Meiser B, Thiery J et al.. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial.  Circulation. 1997;  96 1398-1402
• 20 Wenke K, Meiser B, Thiery J et al.. Simvastatin initiated early after heart transplantation: 8-year prospective experience.  Circulation. 2003;  107 93-97
• 21 Weis M, Pehlivanli S, Meiser B M, von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation.  J Am Coll Cardiol. 2001;  38 814-818
• 22 Ballantyne C M, Short B C, Bourge R C et al.. Lipid treatment and survival after heart transplantation.  J Am Coll Cardiol 31. 1998;  157
• 23 Keogh A, Macdonald P, Kaan A, Aboyoun C, Spratt P, Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation.  J Heart Lung Transplant. 2000;  19 529-537
• 24 Mehra M R, Uber P A, Vivekananthan K et al.. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.  J Am Coll Cardiol. 2002;  40 1609-1614
• 25 Akhlaghi F, Ashley J, Keogh A, Brown K. Cyclosporine plasm unbound fraction in heart and lung transplantation recipients.  Ther Drug Monit. 1999;  21 8-16
• 26 Regazzi M B, Iacona I, Campana C, Gavazzi A, Vigano M, Perani G. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporine A.  Transplant Proc. 1994;  26 2644-2645
• 27 McPherson R, Tsoukas C, Baines M G et al.. Effects of lovastatin on natural killer cell function and other immunological parameters in man.  J Clin Immunol. 1993;  13 439-444
• 28 Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator.  Nat Med. 2000;  6 1399-1402
• 29 Weitz-Schmidt G, Welzenbach K, Brinkmann V et al.. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.  Nat Med. 2001;  7 687-692
• 30 Palinski W, Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis.  J Am Soc Nephrol. 2002;  13 1673-1681
• 31 Finkel T. Oxygen radicals and signaling.  Curr Opin Cell Biol. 1998;  10 248-253
• 32 Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall.  J Cell Biochem. 2001;  82 674-682
• 33 Liao F, Andalibi A, Qiao J H, Allayee H, Fogelman A M, Lusis A J. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice.  J Clin Invest. 1994;  94 877-884
• 34 Collins T, Cybulsky M I. NF-kappa B: pivotal mediator or innocent bystander in atherogenesis?.  J Clin Invest. 2001;  107 255-264
• 35 Sata M, Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis.  J Clin Invest. 1998;  102 1682-1689
• 36 Von Harsdorf R, Li P F, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis.  Circulation. 1999;  99 2934-2941
• 37 Napoli C, Quehenberger O, de Nigris F, Abete P, Glass C K, Palinski W. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells.  FASEB J. 2000;  14 1996-2007
• 38 Jiang C, Ting A T, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.  Nature. 1998;  391 82-86
• 39 Nagy L, Tontonoz P, Alvarez J G, Chen H, Evans R M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-gamma.  Cell. 1998;  93 229-240
• 40 Li A C, Brown K K, Silvestre M J, Willson T M, Palinski W, Glass C K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.  J Clin Invest. 2000;  106 523-531
• 41 Chawla A, Boisvert W A, Lee C H et al.. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis.  Mol Cell. 2001;  7 161-171
• 42 Downward J, Graves J D, Warne P H, Rayter S, Cantrell D A. Stimulation of p21ras upon T-cell activation.  Nature. 1990;  346 719-723
• 43 Casey P J. Protein lipidation in cell signaling.  Science. 1995;  268 221-225
• 44 Ignarro L J, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview.  J Cardiovasc Pharmacol. 1999;  34 879-886
• 45 Davis K L, Martin E, Turko I V, Murad F. Novel effects of nitric oxide.  Annu Rev Pharmacol Toxicol. 2001;  41 203-236
• 46 Laufs U, Liao J K. Direct vascular effects of HMG-CoA reductase inhibitors.  Trends Cardiovasc Med. 2000;  10 143-148
• 47 Guijarro C, Blanco-Colio L M, Ortego M et al.. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture.  Circ Res. 1998;  83 490-500
• 48 Liu L, Moesner P, Kovach N L et al.. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s).  J Biol Chem. 1999;  274 33334-33340
• 49 Essig M, Nguyen G, Prie D, Escoubet B, Sraer J D, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins.  Circ Res. 1998;  83 683-690
• 50 Laufs U, Gertz K, Huang P et al.. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice.  Stroke. 2000;  31 2442-2449
• 51 Wassmann S, Laufs U, Baumer A T et al.. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.  Hypertension. 2001;  37 1450-1457
• 52 Endres M, Laufs U, Huang Z et al.. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.  Proc Natl Acad Sci U S A. 1998;  95 8880-8885
• 53 Laufs U, Liao J K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase.  J Biol Chem. 1998;  273 24266-24271
• 54 Wei X, Si M S, Imagawa D K, Ji P, Tromberg B J, Cahalan M D. Perillyl alcohol inhibits TCR-mediated [Ca(2 + )](i) signaling, alters cell shape and motility, and induces apoptosis in T lymphocytes.  Cell Immunol. 2000;  201 6-13
• 55 Si M S, Ji P, Tromberg B J et al.. Farnesyltransferase inhibition: a novel method of immunomodulation.  Int Immunopharmacol. 2003;  3 475-483
• 56 Maggard M A, Johnson C, Wang T et al.. Inhibition of transplant vasculopathy is associated with attenuated host allo-antibody response.  Transplant Proc. 1999;  31 728-729
• 57 Rose E A, Smith C R, Petrossian G A, Barr M L, Reemtsma K. Humoral immune responses after cardiac transplantation: correlation with fatal rejection and graft atherosclerosis.  Surgery. 1989;  106 203-208
• 58 Michaels P J, Espejo M L, Kobashigawa J et al.. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease.  J Heart Lung Transplant. 2003;  22 58-69
• 59 Maggard M A, Ke B, Wang T et al.. Effects of pravastatin on chronic rejection of rat cardiac allografts.  Transplantation. 1998;  65 149-155